Everyday Health on MSN

What causes primary biliary cholangitis fatigue — and how to get your energy back

Learn about the link between primary biliary cholangitis (PBC) and fatigue, and get tips to restore energy and improve your daily life.
Everyday Health on MSN

Why primary biliary cholangitis causes itching — and how to find relief

Learn why primary biliary cholangitis (PBC) causes intense itching, and explore treatment options, management tips, and skin-care strategies for relief.
Managed Healthcare Executive

FDA approves treatment for debilitating itch in rare liver disease

Lynavoy is used to treat cholestatic pruritus, an extreme itch that affects almost 90% of patients with primary biliary cholangitis.
Healio

Linerixibat lands FDA first for cholestatic pruritus in primary biliary cholangitis

The FDA has approved the first medication for cholestatic pruritus in adult patients with primary biliary cholangitis.The approval of linerixibat (Lynavoy, GSK) — an ileal bile acid transporter ...
MedPage Today on MSN

FDA OKs First Drug for Liver Disease-Related Pruritus

Linerixibat approved for cholestatic itch in primary biliary cholangitis ...
Medical Dialogues

GSK Gets USFDA Nod for Liver Disease-Related Itching Drug Lynavoy

London: The U.S. Food and Drug Administration approved GSK's drug for severe relentless itching caused by ‌a type ⁠of ⁠liver ...
The American Journal of Managed Care

FDA Approves Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis

Linerixibat targets pruritus pathobiology in PBC by blocking ileal bile acid reuptake, aiming to lower circulating pruritogenic bile acid–related mediators. GLISTEN demonstrated greater 24-week WI-NRS ...

GSK granted FDA nod for Lynavoy for itch associated with rare liver disorder

GSK (GSK) stock is in focus as the company wins FDA nod for Lynavoy, the first U.S. treatment for cholestatic pruritus in ...
Medscape

Linerixibat (Lynavoy) for Cholestatic Pruritus Wins FDA Nod

The oral ileal bile acid transporter inhibitor significantly and rapidly reduced cholestatic pruritus in patients with PBC in the phase 3 GLISTEN trial.
pharmaphorum

Alfasigma claims early FDA nod for ex-GSK liver drug

The US regulator confirmed approval of IBAT inhibitor linerixibat, under the Lynavoy trade name, as a treatment for cholestatic pruritus in PBC on 17th March. PBC is a chronic, progressive autoimmune ...
Fierce Pharma

After Alfasigma's GSK licensing deal, Lynavoy picks up FDA nod in rare liver disease

Alfasigma’s buzzer-beater bet on GSK’s rare liver disease prospect has paid off. | Lynavoy is now the first FDA-approved product that can treat cholestatic pruritus in patients with primary biliary ...

GSK hails US FDA approval of Lynavoy for cholestatic pruritis form

GSK PLC on Thursday said the US Food & Drug Administration approved Lynavoy for the treatment of cholestatic pruritus in ...